Gut microbiota diversity in glim-defined malnourished acutely ill older adults

AbstractAnkylosing spondylitis is a male-predominant disease and previous study revealed that estrogens have an anti-inflammatory effect on the spondyloarthritis (SpA) manifestations in zymosan-induced SKG mice. This study aimed to evaluate the effect of selective estrogen receptor modulator (SERM) lasofoxifene (Laso) on disease activity of SpA. Mice were randomized into zymosan-treated, zymosan + 17β-estradiol (E2)-treated, and zymosan + Laso-treated groups. Arthritis was assessed by 18F-fluorodeoxyglucose (18F-FDG) small-animal positron emission tomography/computed tomography and bone mineral density (BMD) was measured. Fecal samples were collected and 16S ribosomal RNA gene sequencing was used to determine gut microbiota differences. Both zymosan + E2-treated mice and zymosan + Laso-treated mice showed lower arthritis clinical scores and lower 18F-FDG uptake than zymosan-treated mice. BMD was significantly higher in zymosan + E2-treated mice and zymosan + Laso-treated mice than zymosan-treated mice, respectively. Fecal calprotectin levels were significantly elevated at 8 weeks after zymosan injection in zymosan-treated mice, but it was not significantly changed in zymosan + E2-treated mice and zymosan + Laso-treated mice. Gut microbiota diversity of zymosan-treated mice was significantly different from zymosan + E2-treated mice and zymosan + Laso-treated mice, respectively. There was no significant difference in gut microbiota diversity between zymosan + E2-treated mice and zymosan + Laso -treated mice. Laso inhibited joint inflammation and enhanced BMD in SKG mice, a model of SpA. Laso also affected the composition and biodiversity of gut microbiota. This study provides new knowledge regarding that selected SpA patients could benefit from SERM treatment.

Download Full-text

The Effects of Increasing Intake of Intact Wheat Fibre or Wheat Bran on Gut Microbiota Diversity: a Systematic Review

Proceedings of The Nutrition Society ◽

10.1017/s0029665120004802 ◽

2020 ◽

Vol 79 (OCE2) ◽

Author(s):

Angie Jefferson ◽

Katie Adolphus

Keyword(s):

Systematic Review ◽

Gut Microbiota ◽

Wheat Bran ◽

Bacterial Species ◽

Microbiota Composition ◽

Inclusion Criteria ◽

Breakfast Cereal ◽

High Fibre ◽

Microbiota Diversity ◽

Gut Microbiota Composition

AbstractThe influence on health of the human gut microbiota is increasingly recognised, however wheat fibre, consumed frequently in Western diets has traditionally been considered inert with regard to gut microbiota composition and metabolic activity. We undertook a systematic review (PRISMA methodology) of human intervention studies examining the effects of intact cereal fibres on gut microbiota composition among healthy adults.(1) Studies published in the past 20 years were identified on PubMed and Cochrane electronic databases. Inclusion criteria were: healthy adult participants, at least one intact cereal fibre (or its sub-fraction) and measurement of faecal microbiota related outcomes. Out of forty studies meeting inclusion criteria, seventeen manipulated wheat fibre/bran or its key constituent arabinoxylans (AXOS), and ten used a whole diet approach with predominantly wheat fibre. Results from these twenty seven wheat fibre papers are presented here. Eight studies provided wheat bran/fibre (ranging from 5.7g-21g/day wheat fibre or 13g-28g/day wheat bran). Three reported significant effects on gut microbiota abundance and/or diversity (both at phyla and species level) and one showed no effect. Six reported significant increases in fermentation metabolites and one reported no significant change. Ten studies manipulated whole day fibre intake (predominantly wheat but also permitting some oats, rye and rice). Wholegrain intake ranged from 80g-150 g per day and fibre from 13.7g–40 g per day. Six found significant increases in bacterial diversity and/or abundance and five showed significant increases in fermentation metabolites. Two identified that response to high fibre intervention is dependent on baseline gut microbiota richness - those with limited richness exhibiting greater microbiota change over time in response to fibre increase. Two reported no significant effects. Nine studies utilised manipulation of AXOS (2.2g–18.8 g per day) with five demonstrating significant increases in target bacterial species and six significant increases in fermentation metabolites. One reported no significant effect to faecal metabolites. This review supports a role for the wheat fibre found in everyday foods (such as bran breakfast cereal of high fibre breads) promoting both microbiota diversity and abundance. While the healthy microbiome is yet to be defined, consumption of a single daily serving of wheat bran fibre appears sufficient to effect gut microbiota fermentation (with demonstrable effects arising from as low as 6g/day), and promote species diversity, with potential benefit to health.However exploration of stability over longer time frames (> 12 weeks) is now required.

Download Full-text

Dysbiosis characteristics of gut microbiota in cerebral infarction patients

Translational Neuroscience ◽

10.1515/tnsci-2020-0117 ◽

2020 ◽

Vol 11 (1) ◽

pp. 124-133

Author(s):

Hao Li ◽

Xiaohui Zhang ◽

Dengdeng Pan ◽

Yongqiang Liu ◽

Xuebing Yan ◽

...

Keyword(s):

Gut Microbiota ◽

Cerebral Infarction ◽

Operating Characteristic ◽

National Institutes Of Health ◽

Diagnostic Model ◽

Healthy Controls ◽

Characteristic Analysis ◽

Rrna Sequencing ◽

Stool Samples ◽

Microbiota Diversity

AbstractObjectiveThe aim of this study is to investigate the dysbiosis characteristics of gut microbiota in patients with cerebral infarction (CI) and its clinical implications.MethodsStool samples were collected from 79 CI patients and 98 healthy controls and subjected to 16S rRNA sequencing to identify stool microbes. Altered compositions and functions of gut microbiota in CI and its correlation with clinical features were investigated. Random forest and receiver operating characteristic analysis were used to develop a diagnostic model.ResultsMicrobiota diversity and structure between CI patients and healthy controls were overall similar. However, butyrate-producing bacteria (BPB) were significantly reduced in CI patients, while lactic acid bacteria (LAB) were increased. Genetically, BPB-related functional genes were reduced in CI patients, whereas LAB-related genes were enhanced. The interbacterial correlations among BPB in CI patients were less prominent than those in healthy controls. Clinically, BPB was negatively associated with the National Institutes of Health Stroke Scale (NIHSS), while LAB was positively correlated with NIHSS. Both BPB and LAB played leading roles in the diagnostic model based on 47 bacteria.ConclusionsThe abundance and functions of BPB in CI patients were significantly decreased, while LAB were increased. Both BPB and LAB displayed promising potential in the assessment and diagnosis of CI.

Download Full-text

Association Between Frailty and Gut Microbiota Metabolite TMAO in Older People With Cardiovascular Disease

Innovation in Aging ◽

10.1093/geroni/igaa057.680 ◽

2020 ◽

Vol 4 (Supplement_1) ◽

pp. 210-211

Author(s):

Wei He ◽

Hua Wang ◽

Jiefu Yang

Keyword(s):

Older Adults ◽

Cardiovascular Diseases ◽

Gut Microbiota ◽

Linear Trend ◽

Frailty Index ◽

Concentration Data ◽

Dependent Relationship ◽

The Status ◽

Cubic Spline Curve ◽

The Relationship

Abstract The potential for the gut microbiota to affect health has particular relevance for older adults. Recent evidence suggests that microbiota-derived metabolites may modulate aging-related changes in immunity, sarcopenia, and cognitive function, all of which are elements of frailty. Trimethylamine N-oxide (TMAO) produced by the metaorganismal metabolism of choline, has been implicated in disease pathogenesis. However, relatively little geroscience research has been carried out on TMAO，and even less on other gut microbiota metabolites. The purpose of this study was to explore the relationship between frailty and circulating TMAO concentration. Data and fasting blood samples came from a prospective comprehensive geriatric assessment cohort of older adults (age≥65, n=451) with cardiovascular diseases. The frailty index based on the accumulated deficits model (48 variables) was used for evaluating the status of frailty. TMAO levels differed between groups with a significant increase for people with frailty (p＜0.001). Compared with the lowest quartile of TMAO levels, patients in the highest quartile had increased 3.07-fold risk of frailty (OR=3.07, 95%CI, 1.69-2.97). After adjusting for age, gender, BMI, history of diseases, hsCRP, LDLc, TMAO levels remained associated with frailty (OR=2.11, 95%CI, 1.01-4.38). Similarly, a cubic spline curve showed a dose-dependent relationship between the odds ratio for the risk of frailty and circulating TMAO in a linear trend (p = 0.006). This study suggests that circulating TMAO are independently associated with frailty in older adult with cardiovascular diseases. Efforts to further characterize the relationship between gut microbiota metabolite and frailty should be further pursued.

Download Full-text

Diversity in the intestinal microbiota and the influence of delivery, dietary profile and nutritional status

Journal of Clinical Images and Medical Case Reports ◽

10.52768/2766-7820/1325 ◽

2021 ◽

Vol 2 (5) ◽

Author(s):

Franciele Valduga ◽

◽

Malena Rostirola Miri ◽

Daniela Signori ◽

Larissa Pereira da Costa ◽

...

Keyword(s):

Nutritional Status ◽

Gut Microbiota ◽

School Children ◽

Alpha Diversity ◽

Grape Juice ◽

Anthropometric Parameters ◽

Culture Methods ◽

Normal Delivery ◽

Significant Difference ◽

Microbiota Diversity

Objective: This research aimed to evaluate the nutritional status and influence on the dietary profile in the gut microbiota, in an attempt to identify possible effects of grape juice consumption among school children aged 6-10. Design: Anthropometric parameters (weight, height, Body Mass Index, waist circumference, triceps, and subscapular skinfold) weremeasured at baseline. A Food Frequency Questionnaire (FFQ) was carried out to evaluate the dietary profile. Feces were analyzed by culture methods and the alpha diversity was determined by the Shannon Index. Participants: 36 volunteer school children aged 6 to 10 years from two different cities in the South of Brazil. Main outcome measure: Gut microbiota diversity according to anthropometric parameters, nutrition profile and delivery patterns. Analysis: For statistical analysis, t or u test and correlation were used through the statistical software SPSS® version 22.0. Results: The volunteers presented a eutrophic nutritional status, but 41.7% in the City 2 were overweight. There was a significant difference in the consumption of polyphenols (p<0.003), microbiotadiversity, breastfeeding, and delivery patterns by city. However, the dietary profile does not include the portions of daily nutrients recommended in both cities. The volunteers from City 1 presented a greater alpha diversity, which may be related to higher micronutrient intake, breastfeeding, and predominant natural/vaginal delivery Conclusion: We observed that the normal delivery and the dietary profile seems to be important factors to the gut microbiota diversity in these children. Keywords: grape juice; dietary profile; gut microbiota.

Download Full-text

Correlation of Gut Firmicutes/Bacteroidetes Ratio with Fibrosis and Steatosis in Patients with Non-alcoholic Fatty Liver Disease

10.21203/rs.3.rs-23643/v1 ◽

2020 ◽

Author(s):

Chyntia Olivia Maurine Jasirwan ◽

Akhmadu Muradi ◽

Irsan Hasan ◽

Marcellus Simadibrata ◽

Ikhwan Rinaldi ◽

...

Keyword(s):

Liver Disease ◽

Gut Microbiota ◽

Fatty Liver ◽

Fatty Liver Disease ◽

Central Obesity ◽

Gastrointestinal Microbiota ◽

Alcoholic Fatty Liver ◽

Microbiota Diversity ◽

Alcoholic Fatty Liver Disease ◽

High Triglyceride

Abstract Background : We investigated the gut microbiota in patients with non-alcoholic fatty liver disease (NAFLD) and its correlation with fibrosis and steatosis as reflected in the controlled attenuation parameter and transient elastography valuesMethods : A cross-sectional study was performed on 37 patients with NAFLD at Cipto Mangunkusumo National General Hospital from December 2018 to March 2019. The gut microbiota was investigated in fecal samples with 16S RNA sequencing using the next-generation sequencing platform MiSeq (Illumina).Results : NAFLD was more common in patients with metabolic syndrome. Firmicutes, Bacteroidetes, and Proteobacteria were the predominant phyla. Bacteroides was more dominant than Prevotella, contrary to the results in previous studies on normal populations in Indonesia. Microbiota dysbiosis was observed in most samples. The gastrointestinal microbiota diversity was significantly decreased in patients with NAFLD with high triglyceride levels and central obesity. The Firmicutes/Bacteroidetes ratio correlated with steatosis and obesity, whereas some other species in the lower taxonomy were mostly correlated with steatosis and obesity without fibrosis. Proteobacteria is the only phylum strongly correlated with fibrosis in patients with normal body mass index.Conclusions : The gut microbiota diversity was decreased in patients with NAFLD with high triglyceride levels and central obesity, and certain gut microbes were correlated with fibrosis and steatosis.

Download Full-text

The Studies to correlation between gut microbiota diversity and functional erectile dysfunction

10.21203/rs.3.rs-454949/v1 ◽

2021 ◽

Author(s):

Qiang Geng ◽

Shaofeng Chen ◽

Yuan Sun ◽

Yu Zhao ◽

Zhong Li ◽

...

Keyword(s):

Erectile Dysfunction ◽

Gut Microbiota ◽

Alpha Diversity ◽

T Test ◽

Data Quality Control ◽

Sequencing Data ◽

Significant Difference ◽

Miseq Platform ◽

Group 3 ◽

Microbiota Diversity

Abstract Objective: To analyze the distribution of gut microbiota in the ED patients, and explore the relationship between the diversity of gut microbiota and psychogenic erectile dysfunction. Methods: 30 cases of patients with erectile dysfunction (ED) and 30 healthy persons (healthy donor, HD) stool specimen were collected, using Illumina's Miseq platform samples V3-V4 region sequences bacterial 16SrRNA gene Paired end (PE) 300 sequencing, sequencing results were analyzed differences in species composition and diversity. Analysis contains five modules: sequencing data quality control, OTU species clustering and annotation, alpha diversity, beta diversity and the use of T-test and the analysis of the LEfSe differences. Results: 1. The flora diversity in the group of ED than HD significantly different (P<0.01), ED group has a low bacterial diversity. 2. Between ED group and HD group, abundant bacteria (TOPlO) and core flora (90%) had no significant difference in the genus level; all bacteria flora (>1%) display, Alloprevotella groups genus presents differences, Alloprevotella only be identified in the HD group. 3. ED and HD groups present in well separated PCoA analysis, having a significant difference in the two kinds of microflora. 4.T-test shows six species were significantly different, in the ED group, Streptococcus and Subdoligranulum were increasing, and Prevotella, Prevotella sp.9, Blautia, Lachnospiraceae NK4A136 groups and Roseburia were decreasing. 5.LEfSe analysis revealed 24 species were significantly different between ED and HD groups. Conclusion: Gene sequencing was performed on the two groups of specimens and finding that microbial community structure and diversity had significant difference, suggesting that ED have low gut microbiota diversity.

Download Full-text

Successful and Safe Treatment of Intestinal Graft-Versus-Host Disease (GvHD) with Pooled-Donor Full Ecosystem Microbiota Biotherapeutics

Blood ◽

10.1182/blood-2019-125540 ◽

2019 ◽

Vol 134 (Supplement_1) ◽

pp. 1993-1993

Author(s):

Florent Malard ◽

Faezeh Legrand ◽

Jérôme Cornillon ◽

Amandine Le Bourgeois ◽

Jean-Baptiste Mear ◽

...

Keyword(s):

Gut Microbiota ◽

Graft Versus Host Disease ◽

Hematopoietic Stem ◽

Host Disease ◽

Graft Versus Host ◽

Steroid Dependent ◽

Gi Symptoms ◽

Microbiota Diversity ◽

Steroid Refractory

Introduction Intestinal Graft-versus-Host Disease (GvHD), following allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT), comes with a high mortality rate and a reduced life-expectancy. In this context, failure to respond to steroid therapy is associated with an absence of further therapeutic options, thereby representing an unmet medical need. A marked reduction in gut microbiota diversity leading to loss of functions was strongly associated with reduced overall survival in GvHD, while a high gut microbiota diversity appears to be protective. Aiming at restoring microbiome functions, Fecal Microbiota Transfer proved to be a promising treatment modality in this challenging clinical situation, with recent studies reporting favorable results in steroid refractory-acute GVHD (SR-aGvHD) patients. Here we report on the use of "MaaT013", a standardized, pooled-donor, high-richness microbiota biotherapeutic, used to treat 8 patients with intestinal-predominant aGvHD. Patients and methods Eight allo-HSCT recipients with steroid-dependent or steroid-refractory gastrointestinal GvHD (classical aGVHD n=3, late-onset aGVHD n=2; aGvHD with overlap syndrome n=3) were treated with the MaaT013 biotherapeutic as part of a compassionate use program. These patients had previously received and failed 1 to 5 lines (median 2.5) of GvHD systemic treatments. MaaT013 microbiota biotherapeutics were provided as a pharmaceutical preparation to hospitals by the developer, "MaaT Pharma". Each patient received 1 to 3 doses (median: 3; total doses administered: 21) of MaaT013, a 150 mL bag, by enema (n=7) or nasogastric tube (n=1). GvHD response was evaluated 7 days after each administration and 28 days after the first dose. Prepared under Good Manufacturing Practices, MaaT013 biotherapeutics are characterized by a highly consistent richness of 455 +/- 3% Operational Taxonomic Units (OTUs) and an Inverse Simpson index greater than 20. Batch release specifications are based on potency (viability), identity (diversity), and purity (microbiological safety testing following regulatory guidelines and proportion of proinflammatory species), ensuring the desired consistency between batches. Results We observed 6/8 positive responses at D28 after first dosing, including 3 Complete Responses (CR), one Very Good Partial Response (VGPR), and 2 Partial Responses (PR). Considering the best GI response achieved, all (8/8) patients experienced at least a PR, with 3 CRs, 2 VGPRs and 3 PRs. The 3 patients with CR were still alive at last follow-up (60 to 192 days after last dosing; median: 115 days) and were able to taper and stop steroids and immunosuppressants without relapse of GI symptoms. Of note, among these 3 patients, mild mouth chronic GvHD symptoms persisted in one patient, and relapse of hematologic malignancy was observed in another patient. Among the 8 treated patients, 5 were still alive at last follow-up (60 to 232 days after last dosing; median: 125 days). The safety of the MaaT013 microbiota biotherapeutic was satisfactory in all patients. One patient developed a possibly related sepsis one day after the third MaaT013 administration. In the latter case, no pathogen was identified in blood cultures, and the patient recovered after a course of antibiotics. Conclusions We herein report for the first time the treatment of 8 patients with steroid-dependent or steroid-refractory intestinal aGvHD using a full ecosystem, standardized, pooled-donor, high-richness biotherapeutic. Overall, 3/8 patients attained a complete response following treatment with the off-the-shelf MaaT013 product, shown to be safe and effective in these immunocompromised patients with severe conditions, warranting further exploration of the full ecosystem microbiota restoration approach. Disclosures Malard: Sanofi: Honoraria; JAZZ pharmaceutical: Honoraria; Astellas: Honoraria; Therakos/Mallinckrodt: Honoraria; Keocyte: Honoraria; Janssen: Honoraria. Plantamura:MaaT Pharma: Employment. Carter:MaaT Pharma: Employment. Chevallier:Jazz Pharmaceuticals: Honoraria; Incyte: Consultancy, Honoraria; Daiichi Sankyo: Honoraria. Blaise:Pierre Fabre medicaments: Honoraria; Molmed: Consultancy, Honoraria; Jazz Pharmaceuticals: Honoraria; Sanofi: Honoraria. Mohty:Jazz Pharmaceuticals: Honoraria, Research Funding.

Download Full-text